Company intelligence / Profile preview
Allorion Therapeutics
- Ownership
- Private
- Development stage
- Other
Overview
Allorion Therapeutics is a clinical-stage biotech company developing next-generation precision medicines, primarily small molecule drugs targeting oncology and autoimmune diseases. Its lead program, ARTS‑021 (CDK2 inhibitor), is in Phase 1/2 clinical trials for advanced solid tumors. The company has also licensed out key assets to partners such as Avenzo Therapeutics and AstraZeneca. Preclinical data support the potential best-in-class status of its CDK2 inhibitor, with additional programs targeting TYK2 and EGFR mutations advancing through preclinical stages.[6][9]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecules[3][5][10]
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Allorion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allorion Therapeutics.